Ziarco planning atopic dermatitis Phase IIb

Ziarco Group Ltd. (Canterbury, U.K.) said ZPL-389 missed the primary endpoint of pruritus as measured on a numerical rating scale vs. placebo in a 98-patient Phase IIa study to treat moderate to severe atopic dermatitis. ZPL-389 did significantly reduce inflammation vs. placebo,

Read the full 426 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE